Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

865 - Triple negative breast cancer and androgen receptor expression: a forerunner for a novel hormonal approach


19 Dec 2015


Poster presentation 1


Prameela Chelakkot G


Annals of Oncology (2015) 26 (suppl_9): 153-155. 10.1093/annonc/mdv534


P. Chelakkot G1, R. Ravind2, S.N. Vijayan3, S. K4, S. V S5, K. Pavithran6

Author affiliations

  • 1 Associate Professor, Department Of Radiation Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 2 Radiation Oncology, HCG Bangalore Institute of Oncology Speciality Centre, Bangalore/IN
  • 3 Department Of Pathology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 4 Radiation Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 5 Department Of Biostatistics, Amrita Institute of Medical Sciences, 682041 - Kochi/IN
  • 6 Department Of Medical Oncology, Amrita Institute of Medical Sciences, 682041 - Kochi/IN


Abstract 865


About 15%-20% of breast cancer is triple negative (TNBC), which carries a poor prognosis. Target molecules investigated in TNBC are, PARP (poly-ADP-ribose polymerase) inhibitor, EGFR (epidermal growth factor receptor) inhibitor and also androgen receptor.


Details of TNBC patients, with follow up till 2011; and retrievable pathological slides and blocks, were analysed for AR status. Slides were reviewed for AR status using Androgen receptor Monoclonal (F39.4.1clone) Mouse antibodies. Slides were de-paraffinised and hydrated. Antigen was heat-retrieved. Horse-radish-peroxidase was used with diamine-benzaldehyde for antibody detection. Androgen receptor positivity was read as percentage and intensity of nuclear staining. Nuclear expression >10% was taken as nuclear positive. All slides were interpreted by a single breast-onco-pathologist.


Of the TNBC patients who had follow up, 72 slides were reviewed for AR status. Three had nuclear AR expression and six had cytoplasmic expression. Mean follow up was 52.53 months. Five year PFS for AR negative was 80.41% and for AR positive 75%. Median PFS was 19.93 months. Cytoplasmic positive group were disease free at the end of follow up. Pre-menopausal, AR positive had five year PFS of 83.3%. Post-menopausal group had median PFS of 19.93 months. Higher grade had less AR expression. Node positive had 5 year PFS of 60%.


AR expression was seen in elderly, post-menopausal, node-positive group as claimed by MacGhan, and Lou et al. AR-positive patients had poor progression-free interval. Luminal androgen receptor (LAR) sub-type of TNBC is identified to have decreased relapse-free-survival and is believed to have AR signaling. Luminal androgen receptor sub-set, encompassing a poor-prognostic group, might be more sensitive to anti-androgen molecules, and can be the sub-set for targeted tailored treatment options, improving the poor outcomes.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings